Compare F5 Inc (FFIV) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs TransMedics Group Inc — how do they compare? F5 Inc trades at $479.83 (market cap $26.14B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: F5 Inc is far larger — about 9.5× TransMedics Group Inc's market cap, and F5 Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and TransMedics Group Inc for 24 Days on average.
| FFIV | TMDX | |
|---|---|---|
Market Cap | $26.14B | $2.74B |
Volume | 503,146 | 949,331 |
Sector | Technology | Health |
52-Week High | $479.83 | $150.42 |
52-Week Low | $223.99 | $61.99 |
Typical Hold Time | 38 Days | 24 Days |
Enterprise Value | $24.78B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $461.66, down 1.07% on the day, with a bullish technical outlook supported by moving averages and a strong fundamental backdrop. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.73 surpassing the $4.00 expectation. Revenue and net income have shown steady growth, reaching $3.09 billion and $692.38 million in 2025, respectively. Positive sentiment is fueled by recent strategic partnerships and industry recognitions, such as being named a Leader in the IDC MarketScape for WAAP platforms.
The stock's valuation appears elevated with a P/E of 36.78 and P/S of 8.07, posing a risk if growth moderates. Analyst consensus is mixed with a $416.60 price target below the current price, suggesting caution despite a majority Hold rating. Key investment opportunities include continued execution on AI security initiatives, while risks involve competitive pressures and reliance on enterprise spending. The stock's proximity to resistance at $468 warrants monitoring for breakout or pullback signals.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
